Leading South African poultry producer Astral Foods has capped a remarkable turnaround by ending its financial year with a R1 billion cash reserve, providing substantial firepower for planned capital investments designed to boost operational efficiency and expand production volumes. The Johannesburg-listed group, one of the country’s largest integrated poultry operators, revealed the robust liquidity position in its full-year results released on Monday, marking a sharp reversal from the severe pressures experienced in recent years.
Group revenue climbed 10.4 per cent to R22.6 billion for the year ended September, with the core poultry division accounting for 82.5 per cent of external sales. Broiler slaughter numbers rose to an average of 5.8 million birds per week, up from 5.4 million in the prior period, reflecting improved flock placements and better biosecurity measures following earlier avian influenza outbreaks. The internal feed division, which supplies the majority of nutritional requirements for Astral’s operations, posted a 9.8 per cent revenue increase to R10.8 billion on the back of higher volumes and firmer pricing. Headline earnings per share advanced 14 per cent to R21.93, while cash generated from operations reached R1.52 billion, bolstered by a R276 million working-capital release from the poultry unit.
Chief executive Gary Arnold described the year as a classic tale of two halves. The first six months remained heavily constrained by elevated input costs and lingering effects of prior disruptions, but a strong second-half rebound—driven by more stable maize and soya prices, reduced load-shedding, and recovering consumer demand—delivered a markedly improved performance. As reported by Business Day, this recovery enabled Astral not only to eliminate net debt but to accumulate R1 billion in gross cash, restoring the balance sheet to its healthiest position in several years and reinstating shareholder distributions with a total dividend payout of R285 million for the period.
The results underscore the success of an aggressive turnaround strategy launched after 2023’s devastating combination of prolonged power cuts and highly pathogenic avian influenza (HPAI) outbreaks that collectively wiped out millions of birds and pushed the group into loss-making territory. Management has since prioritised cost containment, enhanced generator capacity at key sites, and tighter biosecurity protocols. Significantly, on the same day the results were published, the Department of Agriculture granted Astral a vaccination permit authorising inoculation against HPAI at one of its broiler breeder farms—a development that Farmer’s Weeklydescribed as a potential watershed moment for the local industry, which has lost more than R8 billion to bird flu since 2021.
Despite the brighter financial picture, Arnold cautioned that avian influenza remains the single largest risk facing South African poultry producers. He expressed concern that the disease appears to be losing its seasonal pattern and warned that slow progress on a broader vaccination rollout continues to leave the sector vulnerable. Import pressures from subsidised foreign chicken—particularly from Brazil and the United States—also persist, although recent anti-dumping duties and higher global freight rates have offered some relief to local pricing.
Looking ahead, the newly rebuilt cash reserve positions Astral to pursue several high-return projects. These include further expansion of breeder and broiler capacity in Mpumalanga and the Western Cape, upgrades to processing plants to lift throughput, and additional investment in renewable energy and water-security infrastructure to mitigate future utility disruptions. Management emphasised that these initiatives will focus squarely on driving sustainable volume growth while maintaining rigorous cost discipline.
With consumer spending showing tentative signs of improvement and maize prices expected to remain range-bound following an excellent 2025 harvest, Astral believes it is well placed to capitalise on recovering demand for affordable protein. The combination of a fortified balance sheet, resumed dividends, and strategic vaccination approval has markedly lifted investor sentiment, reinforcing the group’s status as a resilient cornerstone of South Africa’s agricultural and food-security landscape.